Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Vodobatinib (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms PROSEEK
- Sponsors Sun Pharma Advanced Research Company
- 29 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 15 May 2023 Planned End Date changed from 1 May 2023 to 1 Mar 2024.
- 15 May 2023 Planned primary completion date changed from 1 May 2023 to 1 Mar 2024.